Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin-Reference-Cited by-同舟云学术

Efficacy of aprepitant for the prevention of chemotherapy-induced nausea and vomiting with a moderately emetogenic chemotherapy regimen: a multicenter, placebo-controlled, double-blind, randomized study in patients with gynecologic cancer receiving paclitaxel and carboplatin

Published:2015-12-10 Issue:3 Volume:21 Page:491-497
ISSN:1341-9625
Container-title:International Journal of Clinical Oncology
language:en
Short-container-title:Int J Clin Oncol

Author:

Yahata Hideaki,Kobayashi Hiroaki,Sonoda Kenzo,Shimokawa Mototsugu,Ohgami Tatsuhiro,Saito Toshiaki,Ogawa Shinji,Sakai Kunihiro,Ichinoe Akimasa,Ueoka Yousuke,Hasuo Yasuyuki,Nishida Makoto,Masuda Satohiro,Kato Kiyoko

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Hematology,General Medicine,Surgery

Link

http://link.springer.com/content/pdf/10.1007/s10147-015-0928-y.pdf

Reference22 articles.

1. Weiderpas E, Sandin S, Inoue M et al (2012) Risk factors for epithelial ovarian cancer in Japan: results from the Japan public health center-based prospective study cohort. Int J Oncol 40(1):21–30

2. Kris MG, Hesketh PJ, Somerfield MR et al (2006) American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol 24:2932–2947

3. Roila F, Fatigoni S (2006) New antiemetic drugs. Ann Oncol 17[Suppl 2]:ii96–ii100

4. Japan Society of Clinical Oncology (2014) Guidelines for appropriate use of antiemetic drugs, version 1.2. Kanehara, Tokyo

5. Ettinger DS, Armstrong DK, Barbour S et al (2012) Antiemesis. J Natl Compr Cancer Netw 10:456–485

Cited by 63 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Defining the clinical benefits of adding a neurokinin-1 receptor antagonist to control chemotherapy-induced nausea and vomiting in moderately emetogenic chemotherapy: a systematic review and meta-analysis of the clinical practice guidelines for antiemesis 2023 from the Japan society of clinical oncology;International Journal of Clinical Oncology;2024-09-11

2. Defining the Clinical Benefits of Adding a Neurokinin-1 Receptor Antagonist to Control Chemotherapy-Induced Nausea and Vomiting in Moderately Emetogenic Chemotherapy: A Systematic Review and Meta-Analysis of the Clinical Practice Guidelines for Antiemesis 2023 from the Japan Society of Clinical Oncology;2024-08-19

3. Olanzapine as Antiemetic Prophylaxis in Moderately Emetogenic Chemotherapy;JAMA Network Open;2024-08-06

4. Evaluation of Efficacy of Adding Aprepitant to Palonosetron and Dexamethasone in Carboplatin and Etoposide Therapy;Biological and Pharmaceutical Bulletin;2024-06-19

5. 2023 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting;ESMO Open;2024-02